Geode Capital Management LLC Purchases 4,372 Shares of Nutriband Inc. (NASDAQ:NTRB)

Geode Capital Management LLC lifted its position in shares of Nutriband Inc. (NASDAQ:NTRB) by 7.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,435 shares of the company’s stock after acquiring an additional 4,372 shares during the period. Geode Capital Management LLC owned approximately 0.56% of Nutriband worth $294,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Haven Private LLC bought a new stake in Nutriband during the fourth quarter worth $54,000. Hedge funds and other institutional investors own 19.70% of the company’s stock.

Analysts Set New Price Targets

Separately, Noble Financial started coverage on Nutriband in a research note on Wednesday, January 22nd. They issued an “outperform” rating and a $13.00 price target on the stock.

Nutriband Stock Performance

Nutriband stock opened at $6.37 on Friday. The stock has a market cap of $70.75 million, a PE ratio of -8.97 and a beta of 1.19. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. Nutriband Inc. has a 12-month low of $3.35 and a 12-month high of $11.78. The business’s 50-day moving average price is $5.97 and its two-hundred day moving average price is $5.70.

Nutriband (NASDAQ:NTRB) last announced its quarterly earnings results on Monday, April 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.06). The company had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.71 million. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%. As a group, analysts expect that Nutriband Inc. will post -0.6 earnings per share for the current fiscal year.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.